SVB Leerink

Selected news for the capital firm - SVB Leerink, collected since 4/2019. Recent stories appear in Daily Political and rivertonroll.com. This capital firm shares healthcare news with Pfizer, Medical Research, Oncology, HealthEquity, AstraZeneca and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
5/8/2021 SVB Leerink Research Analysts Lower Earnings Estimates for Invitae Co. (NYSE:NVTA) - WKRB News wkrb13.com Invitae Co. (NYSE:NVTA) – Stock analysts at SVB Leerink dropped their Q2 2021 earnings estimates for shares of Invitae in a note issued to investors on Tuesday, May 4th. SVB Leerink analyst P. Souda now anticipates that the medical research company will post earnings of ($0.78) per share for the quarter, down from their prior forecast of ($0.55). SVB Leerink currently has a “Outperform” rating and a $50.00 ...
5/8/2021 Q2 2021 EPS Estimates for Globus Medical, Inc. (NYSE:GMED) Increased by SVB Leerink | Daily Political Daily Political Globus Medical, Inc. (NYSE:GMED) – SVB Leerink boosted their Q2 2021 earnings per share estimates for Globus Medical in a note issued to investors on Tuesday, May 4th. SVB Leerink analyst R. Newitter now expects that the medical device company will earn $0.44 per share for the quarter, up from their previous estimate of $0.40. SVB Leerink currently has a “Outperform” rating and a $81.00 target price on ...
5/8/2021 SVB Leerink Equities Analysts Raise Earnings Estimates for Silk Road Medical, Inc (NASDAQ:SILK) dispatchtribunal.com US Crude Prices Plummet 4% as Russia and OPEC Consider Easing CapsSilk Road Medical, Inc (NASDAQ:SILK) – Stock analysts at SVB Leerink raised their Q2 2021 earnings estimates for shares of Silk Road Medical in a note issued to investors on Tuesday, May 4th. SVB Leerink analyst D. Antalffy now anticipates that the company will post earnings per share of ($0.36) for the quarter, up from their previous ...
5/8/2021 Nektar Therapeutics (NASDAQ:NKTR) Trading 8.5% Higher Following Strong Earnings | Daily Political Daily Political ... quarter in the previous year, the business earned ($0.78) EPS. The company’s quarterly revenue was down 53.4% compared to the same quarter last year. Several research analysts have recently commented on the stock. SVB Leerink raised their price objective on shares of Nektar Therapeutics from $20.00 to $21.00 and gave the company a “market perform” rating in a research note on Tuesday, April 13th. Benchmark reissued a “hold ...
5/8/2021 Nektar Therapeutics (NASDAQ:NKTR) Shares Up 8.5% Following Better-Than-Expected Earnings - Ticker Report Ticker Report ... down 53.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.78) EPS.Get Nektar Therapeutics alerts: A number of brokerages recently weighed in on NKTR. SVB Leerink upped their price target on shares of Nektar Therapeutics from $20.00 to $21.00 and gave the stock a “market perform” rating in a research report on Tuesday, April 13th. Mizuho reiterated a “buy ...
5/8/2021 Q2 2021 EPS Estimates for Globus Medical, Inc. Boosted by Analyst (NYSE:GMED) rivertonroll.com Q2 2021 EPS Estimates for Globus Medical, Inc. Boosted by Analyst (NYSE:GMED) Posted by Rob Hiaasen on May 8th, 2021 TweetGlobus Medical, Inc. (NYSE:GMED) – Analysts at SVB Leerink increased their Q2 2021 EPS estimates for shares of Globus Medical in a report issued on Tuesday, May 4th. SVB Leerink analyst R. Newitter now anticipates that the medical device company will post earnings of $0.44 per share ...
5/8/2021 Zacks Investment Research Lowers Organogenesis (NASDAQ:ORGO) to Hold dispatchtribunal.com ... the development, manufacture and commercialization of solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. “ Get Organogenesis alerts:Several other equities research analysts have also recently issued reports on the stock. SVB Leerink raised their price objective on shares of Organogenesis from $19.00 to $22.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 23rd. Credit Suisse Group raised their price ...
5/8/2021 Intellia Therapeutics (NASDAQ:NTLA) Upgraded to “Buy” by Roth Capital slatersentinel.com ... Price Targets reports. The brokerage currently has $80.00 price objective on the stock, up from their previous price objective of $75.00.A number of other research firms have also recently issued reports on NTLA. SVB Leerink restated a buy rating on shares of Intellia Therapeutics in a research report on Sunday, March 21st. Barclays increased their price objective on Intellia Therapeutics from $46.00 to $90.00 and gave the stock an ...
5/8/2021 Intellia Therapeutics (NASDAQ:NTLA) Upgraded to “Buy” at Roth Capital rivertonroll.com ... on Wednesday, February 10th. Raymond James boosted their price target on shares of Intellia Therapeutics from $39.00 to $106.00 and gave the stock an outperform rating in a research report on Friday, January 8th. SVB Leerink restated a buy rating on shares of Intellia Therapeutics in a report on Sunday, March 21st. Truist lifted their target price on shares of Intellia Therapeutics from $40.00 to $80.00 in a research report ...
5/8/2021 Zacks Investment Research Lowers GW Pharmaceuticals (NASDAQ:GWPH) to Strong Sell Mayfield Recorder ... Wainwright cut GW Pharmaceuticals from a “buy” rating to a “neutral” rating and upped their target price for the stock from $162.00 to $220.00 in a research report on Thursday, February 4th. SVB Leerink cut GW Pharmaceuticals from an “outperform” rating to a “market perform” rating and upped their target price for the stock from $200.00 to $220.00 in a research report on Thursday, February 4th ...
5/8/2021 Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Forecasted to Earn Q2 2021 Earnings of $1.76 Per Share The Markets Daily Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Forecasted to Earn Q2 2021 Earnings of $1.76 Per Share Posted by Tristan Rich on May 8th, 2021 // Comments offZimmer Biomet Holdings, Inc. (NYSE:ZBH) – Research analysts at SVB Leerink upped their Q2 2021 earnings per share estimates for Zimmer Biomet in a report released on Tuesday, May 4th. SVB Leerink analyst R. Newitter now anticipates that the medical equipment provider will ...
5/8/2021 Q2 2021 Earnings Forecast for Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Issued By Piper Sandler zolmax.com ... recently issued reports on ZBH. JMP Securities increased their price objective on Zimmer Biomet from $165.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 27th. SVB Leerink increased their price objective on Zimmer Biomet from $200.00 to $205.00 and gave the stock an “outperform” rating in a research report on Wednesday. Wells Fargo & Company increased their price objective on Zimmer ...
5/8/2021 Health Catalyst, Inc. (NASDAQ:HCAT) Expected to Post FY2022 Earnings of ($1.00) Per Share - Watch List News watchlistnews.com ... share for the year. Cantor Fitzgerald has a “Overweight” rating and a $60.00 price target on the stock.Get Health Catalyst alerts: A number of other brokerages have also recently commented on HCAT. SVB Leerink increased their target price on Health Catalyst from $53.00 to $59.00 and gave the company an “outperform” rating in a report on Friday. Piper Sandler boosted their target price on shares of Health ...
5/8/2021 SVB Leerink Increases Zimmer Biomet (NYSE:ZBH) Price Target to $205.00 com-unik.info SVB Leerink Increases Zimmer Biomet (NYSE:ZBH) Price Target to $205.00 Posted by Jared Coughlin on May 8th, 2021Zimmer Biomet (NYSE:ZBH) had its price target lifted by SVB Leerink from $200.00 to $205.00 in a report published on Wednesday, Price Targets.com reports. SVB Leerink currently has an outperform rating on the medical equipment provider’s stock. SVB Leerink also issued estimates for Zimmer Biomet’s Q2 2021 earnings ...
5/8/2021 Analysts Issue Forecasts for Aurinia Pharmaceuticals Inc.'s FY2022 Earnings (NASDAQ:AUPH) - Watch List News watchlistnews.com ... rating on shares of Aurinia Pharmaceuticals in a report on Friday. Zacks Investment Research downgraded Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 27th. SVB Leerink reissued a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Sunday, April 11th. Royal Bank of Canada reduced their target price on Aurinia Pharmaceuticals from $26.00 to $23.00 and set ...
5/8/2021 Equities Analysts Issue Forecasts for Amryt Pharma plc's FY2022 Earnings (NASDAQ:AMYT) baseballnewssource.com ... recently weighed in on AMYT. Maxim Group initiated coverage on Amryt Pharma in a research report on Wednesday, March 31st. They set a “buy” rating and a $27.00 price target for the company. SVB Leerink reaffirmed a “buy” rating and set a $40.00 price target on shares of Amryt Pharma in a research report on Sunday, March 7th. Finally, Zacks Investment Research raised Amryt Pharma from a “sell ...
5/8/2021 ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns “Hold” Rating from Mizuho Ticker Report ... Thursday, January 28th. Royal Bank of Canada lowered their target price on ACADIA Pharmaceuticals from $60.00 to $36.00 and set an “outperform” rating for the company in a report on Tuesday, March 9th. SVB Leerink reduced their price objective on ACADIA Pharmaceuticals from $63.00 to $31.00 and set an “outperform” rating for the company in a research report on Tuesday, April 6th. TheStreet downgraded ACADIA Pharmaceuticals from a ...
5/8/2021 ACADIA Pharmaceuticals (NASDAQ:ACAD) Rating Reiterated by Mizuho | Daily Political Daily Political ... on Tuesday, April 13th. Canaccord Genuity reaffirmed a “hold” rating and set a $26.00 price objective (down from $40.00) on shares of ACADIA Pharmaceuticals in a research report on Tuesday, April 13th. Finally, SVB Leerink cut their target price on shares of ACADIA Pharmaceuticals from $63.00 to $31.00 and set an “outperform” rating for the company in a research report on Tuesday, April 6th. One investment analyst has ...
5/8/2021 Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $495.00 Price Target at Morgan Stanley Mayfield Recorder ... restated a hold rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 13th. Canaccord Genuity restated a buy rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 13th. SVB Leerink boosted their price target on shares of Regeneron Pharmaceuticals from $655.00 to $657.00 and gave the company an outperform rating in a report on Thursday, April 1st. Credit Suisse Group boosted their price target ...
5/8/2021 Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $641.00 by Analysts at SVB Leerink rivertonroll.com Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $641.00 by Analysts at SVB Leerink Posted by Steve ReillyRegeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lowered by SVB Leerink from $657.00 to $641.00 in a research note released on Friday morning, Price Targets.com reports. The brokerage currently has an outperform rating on the biopharmaceutical company’s stock.REGN has been the topic of a number of other research reports ...